Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments |
| |
Authors: | González Carro Pedro Pérez Roldán Francisco De Pedro Esteban Aurora Legaz Huidobro Maria L Soto Fernández Susana Roncero Garcia Escribano Oscar Esteban López-Jamar Jose M Pedraza Martin Carmen Ruíz Carrillo Francisco |
| |
Institution: | Digestive Unit, Hospital General Mancha-Centro, Alcázar de San Juan, Spain. psgc@mixmail.com |
| |
Abstract: | BACKGROUND AND AIM: Even with the current most effective treatment regimens for Helicobacter pylori infection, a considerable number of patients will be resistant to eradication. The aim of the present study was to evaluate the H. pylori eradication rate in patients resistant to standard therapies when treated with a triple therapy of pantoprazole, rifabutin and amoxicillin. METHODS: Ninety-two consecutive patients diagnosed with H. pylori infection resistant to two previous treatment regimens were treated with pantoprazole, rifabutin and amoxicillin for 10 days. The persistence or eradication of H. pylori was determined by a 13C-urea breath test performed 4 weeks after the treatment. RESULTS: Per protocol eradication was achieved in 62.2% of patients and the intention-to-treat eradication was 60.8%. Only two patients were excluded for adverse events related to the treatment. CONCLUSIONS: The eradication rate is acceptable as a third-line therapy, particularly in centers with high cure rate for first line therapy. Another important value of this study is the good tolerance for the treatment observed in our patients. It is possible that rifabutin-based triple therapy may be of use in hospital centers that do not have disposable culture and susceptibility methods against H. pylori. |
| |
Keywords: | Helicobacter pylori rescue therapy rifabutin triple therapy |
本文献已被 PubMed 等数据库收录! |